|
| Press Releases |
|
 |
|
| Friday, June 30, 2023 |
|
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
| Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
| Thursday, June 29, 2023 |
|
|
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始 |
| エーザイ株式会社（本社：東京都）、Gates Ventures（米国、シアトル）、Health Data Research UK（英国、ロンドン、以下、HDR UK）、LifeArc（英国、ロンドン）、およびエジンバラ大学（英国、エジンバラ）は、このたび、2年間の新規共同研究契約を締結したことをお知らせします。 more info >> |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
|
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、東京都文京区(以下、文京区)が実施する2023年度認知症検診事業（以下、本事業）において、当社の認知機能のデジタルチェックツール「のうKNOW(R)」による脳の健康度測定が継続実施されることをお知らせします。 more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイ、米国FDA諮問委員会は全会一致でアルツハイマー病治療薬「LEQEMBI(R)」（レカネマブ）の臨床上のベネフィットを支持 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）の末梢・中枢神経系薬物諮問委員会（Peripheral and Central Nervous System Drugs Advisory Committee、以下 本諮問委員会）が開催され、「LEQEMBI(R)」注射100 mg/mL溶液（一般名：レカネマブ）の臨床第III相Clarity AD検証試験の結果が、本剤の臨床上のベネフィットを示すエビデンスであることが、全会一致で支持されましたのでお知らせします。 more info >> |
|
| Thursday, June 8, 2023 |
|
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
| This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
|
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、韓国において早期アルツハイマー病に係る適応で新薬承認を申請 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、エーザイが抗アミロイドβ（Aβ）プロト フィブリル*抗体レカネマブ（一般名、米国ブランド名：「LEQEMBI(R)」）について、脳内アミロイド病理が確認された早期アルツハイマー病（アルツハイマー病（AD）による軽度認知障害および軽度認知症）に係る適応で、韓国食品医薬品安全処（MFDS）に新薬承認申請を行いましたのでお知らせします。 more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY
Jan 22, 2025 21:00 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) 旗下子公司 Green Rain Solar Inc. 探討在紐約州希臘鎮出售太陽能農場開發權
Jan 22, 2025 21:00 HKT/SGT
|
|
|
MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 22, 2025 17:18 JST
|
|
|
2nd Annual Operational Excellence & Business Transformation Summit: Operational Excellence in The Age of Digital Transformation, Building A Sustainable and Collaborative Future in Asia
Jan 22, 2025 16:15 HKT/SGT
|
|
|
Introducing the Sonim XP400: a 5g Smartphone Engineered for Demanding Days with Unmatched Durability, Now Available in EMEA and Australia
Jan 22, 2025 15:09 HKT/SGT
|
|
|
エーザイ、「世界で最も持続可能な100社」に9回目の選定
Jan 22, 2025 14:40: JST
|
|
|
三菱重工、西武鉄道から西武鉄道山口線向け新型車両3編成（12両）を受注
Jan 22, 2025 14:30: JST
|
|
|
ACN Newswire and Corinium Intelligence Present: CISO Perth 2025 - Uniting Western Australia's Top InfoSec Leaders
Jan 22, 2025 14:28 HKT/SGT
|
|
|
ASEAN Finance Innovation Summit 2025: Unlocking the Future of Finance
Jan 22, 2025 14:25 HKT/SGT
|
|
|
Second Hong Kong Shopping Festival gets underway with seminars and consultancy services
Jan 22, 2025 11:54 HKT/SGT
|
|
|
Migrant Workers Honored at Indian New Year Celebrations
Jan 22, 2025 11:40 HKT/SGT
|
|
|
The Now Corporation（OTC: NWPN）看到加利福尼亞州社區太陽能專案的機會
Jan 21, 2025 21:00 HKT/SGT
|
|
|
The Now Corporation (OTC: NWPN) Sees Opportunities for Community Solar Projects in California
Jan 21, 2025 21:00 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 21, 2025 18:29 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
